Literature DB >> 34775044

A crosslinked dextran sulfate-chitosan nanoparticle for delivery of therapeutic heparin-binding proteins.

Victoria A Guarino1, Adam Blau1, Jack Alvarenga2, Joseph Loscalzo1, Ying-Yi Zhang3.   

Abstract

Negatively charged dextran sulfate (DS)-chitosan nanoparticles (DSCS NPs) contain a DS outer shell with binding properties similar to those of heparin and are useful for the incorporation and delivery of therapeutic heparin-binding proteins. These particles, however, are unstable in physiological salt solutions due to their formation through electrostatic interactions. In the present study, a method was developed to covalently crosslink chitosan in the core of the DSCS NP with a short chain dicarboxylic acid (succinate), while leaving the outer shell of the particle untouched. The crosslinked particles, XDSCS NPs, are stable in NaCl solutions up to 3 M. XDSCS NPs were able to incorporate heparin-binding proteins (VEGF and SDF-1α) rapidly and efficiently, and maintain the full biological activity of the proteins. The incorporated proteins were not released from the particles after a 14-day incubation period at 37 °C in PBS, but retained the same activity as those stored at 4 °C. When aerosolized for delivery to the lungs of rats, XDSCS NP-incorporated SDF-1α showed a ∼17-fold greater retention time compared to that of free protein. These properties suggest that XDSCS NPs could be beneficial for the delivery of therapeutic heparin-binding proteins to achieve sustained in vivo effects.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug delivery; Heparin-binding proteins; Polysaccharide nanoparticles

Mesh:

Substances:

Year:  2021        PMID: 34775044      PMCID: PMC8691175          DOI: 10.1016/j.ijpharm.2021.121287

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  28 in total

1.  Versatile and efficient formation of colloids of biopolymer-based polyelectrolyte complexes.

Authors:  Christophe Schatz; Alain Domard; Christophe Viton; Christian Pichot; Thierry Delair
Journal:  Biomacromolecules       Date:  2004 Sep-Oct       Impact factor: 6.988

Review 2.  Therapeutic proteins.

Authors:  Dimiter S Dimitrov
Journal:  Methods Mol Biol       Date:  2012

Review 3.  The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease.

Authors:  Nathan Karin
Journal:  J Leukoc Biol       Date:  2010-05-25       Impact factor: 4.962

4.  Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis.

Authors:  Franck Peysselon; Sylvie Ricard-Blum
Journal:  Matrix Biol       Date:  2013-11-16       Impact factor: 11.583

5.  Cellular interaction and cytotoxicity of the iowa mutation of apolipoprotein A-I (ApoA-IIowa) amyloid mediated by sulfate moieties of heparan sulfate.

Authors:  Kaori Kuwabara; Kazuchika Nishitsuji; Kenji Uchimura; Shang-Cheng Hung; Makoto Mizuguchi; Hiroyuki Nakajima; Shiho Mikawa; Norihiro Kobayashi; Hiroyuki Saito; Naomi Sakashita
Journal:  J Biol Chem       Date:  2015-08-19       Impact factor: 5.157

6.  Molecular modeling of protein-glycosaminoglycan interactions.

Authors:  A D Cardin; H J Weintraub
Journal:  Arteriosclerosis       Date:  1989 Jan-Feb

7.  SDF-1α in glycan nanoparticles exhibits full activity and reduces pulmonary hypertension in rats.

Authors:  Tao Yin; Andrew R Bader; Tim K Hou; Bradley A Maron; Derrick D Kao; Ray Qian; Daniel S Kohane; Diane E Handy; Joseph Loscalzo; Ying-Yi Zhang
Journal:  Biomacromolecules       Date:  2013-10-18       Impact factor: 6.988

Review 8.  Heparin and heparan sulfate: analyzing structure and microheterogeneity.

Authors:  Zachary Shriver; Ishan Capila; Ganesh Venkataraman; Ram Sasisekharan
Journal:  Handb Exp Pharmacol       Date:  2012

Review 9.  Glycosaminoglycan-Protein Interactions: The First Draft of the Glycosaminoglycan Interactome.

Authors:  Sylvain D Vallet; Olivier Clerc; Sylvie Ricard-Blum
Journal:  J Histochem Cytochem       Date:  2020-08-06       Impact factor: 2.479

Review 10.  Nanosized Delivery Systems for Therapeutic Proteins: Clinically Validated Technologies and Advanced Development Strategies.

Authors:  Filippo Moncalvo; Maria Isabel Martinez Espinoza; Francesco Cellesi
Journal:  Front Bioeng Biotechnol       Date:  2020-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.